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Study of drug resistance began in the
late 1940’s, and recognition that altered
membrane transport of drug was often
related to cellular drug resistance followed
approximately 20 years later. Identification
and isolation of specific membrane pro-
teins that influence this altered drug trans-
port began in the 1970’s and is a major
ongoing endeavor to this day. In this arti-
cle, we refer to such proteins as “drug
resistance associated membrane proteins,”
or “DRAMPs.” In over 40 years, dozens of
books and tens of thousands of research
articles have asked how drug resistance is
mediated by various DRAMPs. By com-
parison, relatively few studies have probed
the normal physiological function of these
proteins. In many cases, deletion of the
gene encoding a DRAMP is not lethal,
showing that the function of the pro-
tein is non-essential, but in some cases
(e.g., PfCRT protein involved in antimalar-
ial drug resistance) deletion is not possi-
ble, suggesting an essential function. For
some DRAMPs a clear role in specific
cell biological processes has been estab-
lished (e.g., Ishikawa et al., 1997; Jin
et al., 2002; Baugh et al., 2012; Quazi and
Molday, 2013), but in most cases we are
no closer to a detailed molecular definition
of the physiologic function of DRAMPs
than we were when these proteins were
first discovered. When they are involved
in drug resistance, DRAMPs are often
either mutated or overexpressed, and in
some cases both. Quantitative comparison
between wild type and mutant isoforms of
DRAMPs, or between normal and higher
levels, is often quite difficult for a variety
of technical reasons, and this has proba-
bly slowed elucidation of their physiologic
function.
The vast majority of genetic, bio-
chemical, biophysical, and cell biological
studies with DRAMPs have emphasized
their putative interactions with drugs,
and dozens of review articles summarize
decades of such work (e.g., Saidijam et al.,
2006; Bay et al., 2008; Blair and Piddock,
2009; Damme et al., 2011). The known
array of DRAMPs is now dizzying, with
hundreds of proteins now organized into
five families (ABC, MATE, MFS, SMR,
RND), as described elsewhere (Alvarez-
Ortega et al., 2013). Members of each
family can be found in multiple phyla,
but sequence conservation across phyla is
typically quite low. Individual members
of these families have been implicated in
anticancer, antibacterial, antifungal, and
antiparasitic drug resistance phenomena.
Other papers in this volume describe spe-
cific proteins in detail. Collectively, these
data related to DRAMP structure and
function and their roles in drug resis-
tance are exceedingly rich, and encompass
a remarkable diversity of function. It is
therefore a challenge to view them as a
single class of proteins, since their only
common thread is participation in drug
resistance phenomena, which are biologi-
cally and chemically quite diverse.
To add additional complexity, there are
four possible routes to cellular drug resis-
tance: (1) catabolism of the drug, (2)
mutation and/or altered expression of the
drug target, (3) switching off a relevant
metabolic pathway or (4) altered cellular
transport of the drug. All operate sim-
ply to reduce the efficiency of interac-
tion between the drug and its molecular
target, and membrane proteins involved
in drug resistance phenomena could in
theory influence any of the four routes.
To date, most DRAMPs studied in depth
have been associated with altered drug
transport phenomena that act to pro-
mote lower drug-drug target association.
The most famous of these is human
MDR1 protein (P-glycoprotein), which
mediates decreased accumulation of anti-
cancer drugs in tumor cells (Roepe et al.,
1996; Quazi and Molday, 2013). Early
on it was appreciated that altered drug
transport induced by overexpression of
huMDR1 could in theory be direct or
indirect (Roepe et al., 1996), meaning
huMDR1 could mediate direct transloca-
tion of drugs back out of the cell to reduce
net accumulation, or indirectly influence
accumulation of drugs through physical
chemical effects, such as changes in mem-
brane potential that would then effect
passive influx of some drugs (Wadkins
and Roepe, 1997). Decades later, mul-
tiple examples of both direct and indi-
rect phenomena can be found for various
examples of drug resistance mediated by
DRAMPs. Another question raised early
on was whether degrees of resistance or
patterns of drug “cross resistance” were
mediated solely by huMDR1 and other
DRAMPs. In addressing this question, of
note is the fact that many early mod-
els of drug resistant cells were created by
incremental exposure to increasing con-
centrations of a single drug (Biedler and
Riehm, 1970), protocols that induce a
variety of “epi-phenomena” that are now
known to add to drug resistance, along
with DRAMPs. For example, it is now
appreciated that the 100–1000’s-fold lev-
els of drug resistance observed in early
drug selected tumor cell models are clearly
not due to huMDR1 overexpression alone.
A crucial concept that emerged from this
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period is that altered cell signaling related
to programmed cell death is likely more
relevant for high levels of drug resistance
in many cancers, relative to the contribu-
tion made by ABC DRAMPs (Lowe et al.,
1993; Borst, 2012).
A central, remaining question for most
of these proteins is what functions do
DRAMPs have in the absence of drugs to
which resistance has been selected? Even
if not essential in many cases, clearly
these functions are important since the
proteins are chromosomally encoded, are
found in all phyla, and have been evolv-
ing for millions of years. As one exam-
ple, even in the absence of man-made
drug pressure for isolated microbiomes,
some intrinsically drug resistant bacteria
have been discovered suggesting that one
normal physiologic function is conferring
resistance to commensal defensins or other
excreted natural antibiotics (Bhullar et al.,
2012). Most drug resistance researchers
believe that definition of these “normal”
or “physiologic” functions will better illu-
minate the molecular mechanism of how
the membrane proteins confer drug resis-
tance. In examples where intrinsic drug
resistance is not the physiologic func-
tion, presumably, mutations or increased
expression seen for these proteins in drug
selected cells confers drug resistance via
the normal function being “hijacked” or
altered in such a way as to reduce inter-
action between drug and drug target. But
beyond the example of “naturally resis-
tant” bacteria (Bhullar et al., 2012), what
are those normal functions?
Other bacterial DRAMPs have been
associated with a variety of natural
functions that include: spermidine degra-
dation, pH homeostasis, alkali tolerance,
removal of fatty acids, bile salts, homoser-
ine lactones, or aromatic hydrocarbons
(Neyfakh, 1997; Krulwich et al., 2005;
Fernándex and Hancock, 2012). For
huMDR1 and itsmany relatives in the ABC
transporter superfamily, the most illumi-
nating early experiments came from gene
knockout experiments with mice (Smit
et al., 1993). Here, Borst and colleagues
showed a distinct tissue/cellular pheno-
type associated with deletion of murine
orthologs of huMDR1, namely, altered
traffic of phospholipids. This suggests that
the normal function of huMDR1 may
include maintenance of cell membrane
lipid disposition, or direct transport of
phospholipids and related molecules.
These hypotheses were supported in sev-
eral follow-up reports (e.g., van Helvoort
et al., 1996; Raggers et al., 2000; Romsicki
and Sharom, 2001). Work in this area
remains ongoing, and the only universally
accepted conclusion at this point seems
to be that there is a wider-than-expected
diversity of natural substrates for ABC
transporters involved in drug resistance
phenomena.
Another important class of DRAMPs
is comprised of those involved in anti-
parasitic drug resistance. Although they
are not the only mechanism that con-
fers resistance, transporters have been
implicated in drug resistance for the
microorganisms that cause schistosomi-
asis (Kasinathan and Greenberg, 2012),
leishmaniasis (Aït-Oudhia et al., 2011),
sleeping sickness (Wilkinson and Kelly,
2009), malaria (Roepe, 2011), and other
parasitic diseases. Perhaps the most heav-
ily studied to data are malaria DRAMPs.
These include orthologs of huMDR1 and
huMRP that are found in multiple species
of malarial parasites, including P. falci-
parum and P. vivax. Early on Wilson et al.
(1989) and Foote et al. (1990), PfMDR1
was thought to be the major contributor to
the most widespread form of antimalarial
drug resistance [chloroquine (CQ) resis-
tance, (CQR)], however, mutations in a
novel DRAMP with no known orthologs
in other eukaryotes, called PfCRT, was
subsequently found to be responsible for
a much larger portion of the shift in
CQ cytostatic activity (CQ IC50) observed
for CQR P. falciparum (Fidock et al.,
2000). Multiple mutations in the pfcrt gene
are required for CQR, and these confer
patterns of amino acid substitutions in
the encoded PfCRT protein. The patterns
reveal the geographic origin of the CQR
strain or isolate and also suggest different
cross-resistance patterns to related drugs
(Summers et al., 2012). There are now at
least 29 distinct isoforms of PfCRT known
to exist, with each isoform selected by dif-
ferent drug-use histories in the respective
geographic origin (Baro et al., 2013). For
at least a decade, it has been widely sus-
pected that these PfCRTmutations may be
all that is necessary to confer resistance to
multiple quinoline antimalarial drugs, and
perhaps other compounds.
Recently however, in set of observations
oddly reminiscent of the now-accepted
concept that huMDR1 protein overexpres-
sion is only part of the explanation for
tumor multidrug resistance, we now know
that PfCRT mutations are only part of the
story for CQR. From cancer cells to malar-
ial parasites, altered signaling related to
drug induced programmed cell death also
appears necessary for high-level drug resis-
tance (e.g., Lowe et al., 1993; Gaviria et al.,
2013). Using progeny of an available CQR
× CQS parasite genetic cross, a very recent
paper shows that the genetics of “cytostatic
CQR” (resistance to cytostatic, or growth
inhibitory, effects of the drug) are distinct
from those of cytocidal CQR (resistance
to cytocidal, or parasite kill, effects of the
drug) (Gaviria et al., 2013). That is, sim-
ilar to high levels of tumor cell multidrug
resistance, and other examples of bacterial,
fungal, and parasite drug resistance, it now
appears likely that a DRAMP (PfCRT) is
responsible for one key layer to antimalar-
ial drug resistance, with altered signaling
related to parasite cell death adding to the
phenotype upon acquisition of high lev-
els of cytocidal drug resistance (Sinai and
Roepe, 2012; Gaviria et al., 2013; Roepe,
2014).
What does this tell us about studies
that probe DRAMP physiologic function?
An important lesson is that defining phys-
iologic function using drug pressured or
drug selected cell lines can confuse analysis
due to the presence of unforeseen epi-
phenomena, such as altered metabolism
and signal transduction related to cell
death pathways. Similar to defining the
precise contribution of the DRAMP
to drug resistance, it can be difficult in
these drug selected systems to unambigu-
ously define physiologic function because
other epi-phenomena are present. Direct
gene knockout experiments can in some
cases be informative, except of course in
examples where the DRAMP is essen-
tial for cell viability (Waller et al., 2003).
The ultimate goal for molecular defini-
tion of DRAMP function is purification
and reconstitution into a lipid bilayer or
proteoliposome preparation, followed by
direct molecular assays. A number of such
experiments have been done for huMDR1
and other eukaryotic ABC transporters
(e.g., Sharom et al., 1993; Ambudkar et al.,
1998; Howard and Roepe, 2003), bacterial
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DRAMPs (e.g., Yerushalmi et al., 1995),
and even malarial DRAMPs (Paguio et al.,
2009). Some of these studies have been
used to query possible natural substrates,
but many more such experiments are
needed.
Even once the protein is purified
and reconstituted, functional assays for
DRAMPs can be quite difficult, in part
because the suspected transporter sub-
strates are often hydrophobic molecules
or lipophilic metabolites. Also, some
DRAMPs may not even be transporters,
but signaling receptors involved in cell
death that require yet unknown co-factors.
In the case of hydrophobic substrates, rou-
tine transport assays that separate pro-
teoliposomes from substrate at various
time points via centrifugation or filtra-
tion have very high background due to
the substrate adhering to lipid, filters, etc.
Another approach that shows promise,
at least for known substrates, is to use
a fluorometric substrate analog wherein
a fluorescent signal can be used to dis-
tinguish drug on one side of a mem-
brane vs another. For example, this has
recently been used to monitor CQ trans-
port by PfCRT (Paguio et al., 2009). This
analysis reveals features of drug trans-
port by PfCRT that are not possible to
monitor with other approaches (Roepe,
2011).
Yet, similar to most other DRAMPs,
for PfCRT, and PfMDR1, we still have
no unequivocal molecularly defined func-
tion for the protein in normal cell phys-
iology. For PfCRT cell biological clues
abound, and in particular include some
evidence for a role in organellar volume
regulation, ionic equilibria, hemoglobin
metabolism, and perhaps glutathione traf-
fic (Bennett et al., 2004; Gligorijevic et al.,
2006; Patzewitz et al., 2013; Lewis et al.,
2014). Further testing these hypotheses,
with purified protein in reconstituted sys-
tems such as proteoliposomes and bilayers,
remains an important goal as is the case
for all DRAMPs. The papers in this volume
offer invaluable guidance in this ongoing
endeavor.
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